Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000, 343: 1594-1602. 10.1056/NEJM200011303432202.
Article
CAS
PubMed
Google Scholar
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, et al: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999, 130: 478-486.
Article
CAS
PubMed
Google Scholar
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003, 48: 35-45. 10.1002/art.10697.
Article
CAS
PubMed
Google Scholar
Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, Stein LD, Gedalia A, Ilowite NT, Wallace CA, et al: Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003, 48: 218-226. 10.1002/art.10710.
Article
CAS
PubMed
Google Scholar
Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003, 48: 1667-1675. 10.1002/art.11017.
Article
CAS
PubMed
Google Scholar
Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, et al: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002, 359: 1187-1193. 10.1016/S0140-6736(02)08215-6.
Article
CAS
PubMed
Google Scholar
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000, 356: 385-390. 10.1016/S0140-6736(00)02530-7.
Article
CAS
PubMed
Google Scholar
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, et al: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999, 354: 1932-1939. 10.1016/S0140-6736(99)05246-0.
Article
CAS
PubMed
Google Scholar
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004, 50: 1400-1411. 10.1002/art.20217.
Article
CAS
PubMed
Google Scholar
Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BHC: Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology. 2001, 40: 1317-1319. 10.1093/rheumatology/40.11.1317.
Article
CAS
PubMed
Google Scholar
Brion PH, Mittal HA, Kalunian KC: Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med. 1999, 131: 634-
Article
CAS
PubMed
Google Scholar
Kent PD, Davis JM, Davis MDP, Matteson EL: Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum. 2002, 46: 2257-2258. 10.1002/art.10348.
Article
PubMed
Google Scholar
Misery L, Perrot JL, Gentil PA, Pallot PB, Cambazard F, Alexandre C: Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol. 2002, 146: 334-335. 10.1046/j.1365-2133.2002.4653_4.x.
Article
CAS
PubMed
Google Scholar
Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC: Cutaneous drug eruption to infliximab: Report of 4 cases with an interface dermatitis pattern. Arch Dermatol. 2002, 138: 1258-1259. 10.1001/archderm.138.9.1258.
Article
PubMed
Google Scholar
Wright RC: Atopic dermatitis-like eruption precipitated by infliximab. JAm Acad Dermatol. 2003, 49: 160-161.
Article
Google Scholar
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.
Article
CAS
PubMed
Google Scholar
Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis. 2003, 62 (Suppl 2): ii30-ii33.
PubMed Central
CAS
PubMed
Google Scholar
Rau R, Sander O, van Riel PL, van de Putte LB, Hasler F, Zaug M, Kneer J, van der AP, Stevens RM: Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. J Rheumatol. 2003, 30: 680-690.
CAS
PubMed
Google Scholar
Welsing PMJ, van Riel PLCM: The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol. 2004, 31: 14-21.
Google Scholar
Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38: 44-48.
Article
CAS
PubMed
Google Scholar
Stern R, Wintroub BU: Cutaneous reactions to drugs. Fitzpatrick's Dermatology in General Medicine. Edited by: Freedberg IM, Eisen A, Wolff K, Austen KF, Goldsmith LA, Katz SI. 1999, New York: McGraw-Hill, 1634-1642. 5
Google Scholar
Jorizzo JL, Daniels JC: Dermatologic conditions reported in patients with rheumatoid arthritis. J Am Acad Dermatol. 1983, 8: 439-457.
Article
CAS
PubMed
Google Scholar
Sibbitt WL, Williams RC: Cutaneous manifestations of rheumatoid arthritis. Int J Dermatol. 1982, 21: 563-572.
Article
PubMed
Google Scholar
Yamamoto T, Ohkubo H, Nishioka K: Skin manifestations associated with rheumatoid arthritis. J Dermatol. 1995, 22: 324-329.
Article
CAS
PubMed
Google Scholar
Bicer A, Tursen U, Cimen OB, Kaya TI, Ozisik S, Ikizoglu G, Erdogan C: Prevalence of dermatophytosis in patients with rheumatoid arthritis. Rheumatol Int. 2003, 23: 37-40.
Article
PubMed
Google Scholar
Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002, 46: 2287-2293. 10.1002/art.10524.
Article
PubMed
Google Scholar
Wilkinson SM, Smith AG, Davis MJ, Mattey DL, Dawes PT: Suspected cutaneous drug toxicity in rheumatoid arthritis – an evaluation. Br J Rheumatol. 1993, 32: 798-803.
Article
CAS
PubMed
Google Scholar
van der Veen MJ, van der HA, Kruize AA, Bijlsma JW: Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1994, 53: 224-228.
Article
PubMed Central
CAS
PubMed
Google Scholar
Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, Mayes MD, Varga J, Medsger TA, Love LA: Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum. 2000, 43: 243-249. 10.1002/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K.
Article
CAS
PubMed
Google Scholar
Bresnihan B, Cunnane G: Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am. 2003, 29: 185-202. 10.1016/S0889-857X(02)00101-1.
Article
PubMed
Google Scholar
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001, 345: 1098-1104. 10.1056/NEJMoa011110.
Article
CAS
PubMed
Google Scholar
Hyrich KL, Silman AJ, Watson KD, Symmons DP: Anti-tumour necrosis factor {alpha} therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. 2004, 63: 1538-1543. 10.1136/ard.2004.024737.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ellerin T, Rubin RH, Weinblatt ME: Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003, 48: 3013-3022. 10.1002/art.11301.
Article
CAS
PubMed
Google Scholar
Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ: Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum. 2003, 48: 1853-1857. 10.1002/art.11151.
Article
CAS
PubMed
Google Scholar
Chan AT, Cleeve V, Daymond TJ: Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J. 2002, 78: 47-48. 10.1136/pmj.78.915.47.
Article
PubMed Central
CAS
PubMed
Google Scholar
Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL: Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001, 76: 653-656.
Article
CAS
PubMed
Google Scholar
Hernandez-Cruz B, Cardiel MH, Villa AR, Alcocer-Varela J: Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. J Rheumatol. 1998, 25: 1900-1907.
CAS
PubMed
Google Scholar
Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC: Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol. 2004, 31: 1912-1917.
CAS
PubMed
Google Scholar
Hartung AD, Bohnert A, Hackstein H, Ohly A, Schmidt KL, Bein G: Th2-mediated atopic disease protection in Th1-mediated rheumatoid arthritis. Clin Exp Rheumatol. 2003, 21: 481-484.
CAS
PubMed
Google Scholar
Hilliquin P, Allanore Y, Coste J, Renoux M, Kahan A, Menkes CJ: Reduced incidence and prevalence of atopy in rheumatoid arthritis. Results of a case-control study. Rheumatology. 2000, 39: 1020-1026. 10.1093/rheumatology/39.9.1020.
Article
CAS
PubMed
Google Scholar
Rudwaleit M, Andermann B, Alten R, Sorensen H, Listing J, Zink A, Sieper J, Braun J: Atopic disorders in ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis. 2002, 61: 968-974. 10.1136/ard.61.11.968.
Article
PubMed Central
CAS
PubMed
Google Scholar
Olsson AR, Wingren G, Skogh T, Svernell O, Ernerudh J: Allergic manifestations in patients with rheumatoid arthritis. APMIS. 2003, 111: 940-944. 10.1034/j.1600-0463.2003.1111004.x.
Article
PubMed
Google Scholar
Krueger JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002, 46: 1-23. 10.1067/mjd.2002.120568.
Article
PubMed
Google Scholar
Carlson E, Rothfield N: Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 2003, 48: 1165-1166. 10.1002/art.11033.
Article
PubMed
Google Scholar
Favalli E, Sinigaglia L, Varenna M, Arnoldi C: Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002, 11: 753-755. 10.1191/0961203302lu236cr.
Article
CAS
PubMed
Google Scholar
Shakoor N, Michalska M, Harris CA, Block JA: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002, 359: 579-580. 10.1016/S0140-6736(02)07714-0.
Article
CAS
PubMed
Google Scholar
Geborek P, Crnkic M, Petersson IF, Saxne T: Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002, 61: 793-798. 10.1136/ard.61.9.793.
Article
PubMed Central
CAS
PubMed
Google Scholar
Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P: Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003, 30: 2287-2291.
PubMed
Google Scholar
McCain ME, Quinet RJ, Davis WE: Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology. 2002, 41: 116-117. 10.1093/rheumatology/41.1.116.
Article
CAS
PubMed
Google Scholar
Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001, 357: 1842-1847. 10.1016/S0140-6736(00)04954-0.
Article
CAS
PubMed
Google Scholar
Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, et al: A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003, 139: 1627-1632. 10.1001/archderm.139.12.1627.
Article
CAS
PubMed
Google Scholar
Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E: Psoriasiform eruption induced by infliximab. Ann Pharmacother. 2004, 38: 54-57. 10.1345/aph.1C477.
Article
PubMed
Google Scholar